Delivery Order SPE2DB20D3101-SPE2DB25FRUT8
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $40,273.98 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors. This firm fixed price, non-set-aside contract was awarded on August 25, 2025, with an ultimate completion date of August 26, 2025. The pharmaceutical products will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. Repatha is a PCSK9 inhibitor used to treat high...
- The Defense Logistics Agency awarded a delivery order valued at $17,390.89 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with performance in Conshohocken, Pennsylvania and completion targeted for July 31, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global...
- The Defense Logistics Agency awarded a $27,040.46 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with a completion date of September 3, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,221.17 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with performance in Conshohocken, Pennsylvania. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 29, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $1 billion and extends...
- The Defense Logistics Agency awarded a delivery order valued at $5,997.38 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 29, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, supplying brand-name and generic...
- The Defense Logistics Agency awarded a $44,398.54 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors. This competitive, firm fixed-price contract was executed on August 20, 2025, with an ultimate completion date of August 21, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $5,707.30 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with performance at the contractor's Conshohocken, Pennsylvania facility. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 28, 2025, and represents a non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical supply vendor, fulfills this...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with a completion date of July 23, 2025. This non-competitive, firm fixed-price delivery order was issued on July 22, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Repatha is a prescription medication used to treat high cholesterol and reduce the risk of cardiovascular disease. This...
- The Defense Logistics Agency awarded a delivery order valued at $47,042.90 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement of pharmaceutical products for federal medical supply needs. The award was made to AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, the company's headquarters and primary...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRUT8Delivery Order
The Defense Logistics Agency awarded a $14,259.85 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with performance in Conshohocken, Pennsylvania and completion targeted for September 9, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. Repatha is a PCSK9 inhibitor prescribed for managing high cholesterol and reducing cardiovascular risk, indicating the product supports military healthcare system requirements for specialty pharmaceutical therapies. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement through the DLA's comprehensive global pharmaceutical supply vehicle. The company maintains an extensive portfolio of delivery orders covering brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. This award exemplifies the company's role as a primary source for military health system pharmaceutical needs and reflects DLA's strategy of leveraging established prime vendor relationships to ensure reliable access to specialty medications and biologics for defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.3k | 9/8/25 |